RGTI, or Regulus Therapeutics, is attracting investor interest due to its innovative RNA-targeted therapeutics and positive clinical trial results. The company’s focus on biotechnology aligns with increasing healthcare investments. While growth potential exists, the sector’s volatility necessitates thorough research and caution from investors.